{"id":"NCT01893138","sponsor":"Cook MyoSite","briefTitle":"Autologous Muscle Derived Cells for Female Urinary Sphincter Repair","officialTitle":"A Double-blind, Randomized, Controlled Trial Comparing the Safety and Efficacy of AMDC-USR With Placebo in Female Subjects With Stress Urinary Incontinence","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2013-11-21","primaryCompletion":"2019-11-01","completion":"2020-11-10","firstPosted":"2013-07-08","resultsPosted":"2023-01-05","lastUpdate":"2023-01-05"},"enrollment":311,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"QUADRUPLE","primaryPurpose":"TREATMENT"},"conditions":["Stress Urinary Incontinence"],"interventions":[{"type":"OTHER","name":"Placebo","otherNames":[]},{"type":"BIOLOGICAL","name":"Iltamiocel","otherNames":["Autologous muscle-derived cells (AMDC)"]}],"arms":[{"label":"Placebo","type":"PLACEBO_COMPARATOR"},{"label":"Iltamiocel","type":"EXPERIMENTAL"}],"summary":"This randomized, double-blind, placebo-controlled, multicenter, confirmatory study will evaluate the efficacy and safety of Cook MyoSite Incorporated Autologous Muscle-Derived Cells (generic name Iltamiocel) compared to a placebo (vehicle) control dose in the treatment of stress urinary incontinence (SUI) in adult female patients.","primaryOutcome":{"measure":"Participants With â‰¥ 50% Reduction in Stress Incontinence Episode Frequency From Baseline to 12 Months Post-treatment; as Assessed by 3 Day Diary","timeFrame":"Baseline and 12 months","effectByArm":[{"arm":"Iltamiocel","deltaMin":103,"sd":null},{"arm":"Placebo","deltaMin":52,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":10},"locations":{"siteCount":29,"countries":["United States","Belgium","Germany"]},"refs":{"pmids":["39282854","28734829"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":11,"n":199},"commonTop":["Urinary tract infection","Dysuria","Sinusitis","Back pain","Injection site pain"]}}